GC Wealth Management RIA LLC Sells 225 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

GC Wealth Management RIA LLC cut its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 9.4% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 2,168 shares of the biopharmaceutical company’s stock after selling 225 shares during the quarter. GC Wealth Management RIA LLC’s holdings in Gilead Sciences were worth $200,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the company. Citizens Financial Group Inc. RI raised its holdings in Gilead Sciences by 58.6% in the fourth quarter. Citizens Financial Group Inc. RI now owns 10,027 shares of the biopharmaceutical company’s stock worth $926,000 after purchasing an additional 3,706 shares in the last quarter. Pzena Investment Management LLC increased its holdings in shares of Gilead Sciences by 22.8% during the fourth quarter. Pzena Investment Management LLC now owns 3,223 shares of the biopharmaceutical company’s stock valued at $298,000 after acquiring an additional 599 shares in the last quarter. Sage Mountain Advisors LLC increased its holdings in shares of Gilead Sciences by 20.1% during the fourth quarter. Sage Mountain Advisors LLC now owns 6,112 shares of the biopharmaceutical company’s stock valued at $565,000 after acquiring an additional 1,023 shares in the last quarter. Ranch Capital Advisors Inc. increased its holdings in shares of Gilead Sciences by 57.7% during the fourth quarter. Ranch Capital Advisors Inc. now owns 19,555 shares of the biopharmaceutical company’s stock valued at $1,806,000 after acquiring an additional 7,153 shares in the last quarter. Finally, Independent Advisor Alliance increased its holdings in shares of Gilead Sciences by 35.4% during the fourth quarter. Independent Advisor Alliance now owns 32,128 shares of the biopharmaceutical company’s stock valued at $2,968,000 after acquiring an additional 8,398 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors.

Insider Transactions at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total value of $228,375.00. Following the completion of the transaction, the chief financial officer now directly owns 129,873 shares of the company’s stock, valued at approximately $11,863,898.55. This represents a 1.89 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold a total of 311,285 shares of company stock valued at $31,284,910 in the last three months. 0.16% of the stock is currently owned by company insiders.

Gilead Sciences Trading Down 0.4 %

Shares of GILD stock opened at $113.99 on Thursday. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. The company has a market cap of $141.96 billion, a price-to-earnings ratio of 308.08, a PEG ratio of 0.71 and a beta of 0.21. The stock has a 50 day simple moving average of $100.99 and a 200-day simple moving average of $92.33. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $119.96.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. On average, equities research analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 28th. Stockholders of record on Friday, March 14th will be paid a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a dividend yield of 2.77%. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.77. The ex-dividend date of this dividend is Friday, March 14th. Gilead Sciences’s dividend payout ratio is presently 854.05%.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the stock. Royal Bank of Canada upped their price objective on shares of Gilead Sciences from $84.00 to $90.00 and gave the company a “sector perform” rating in a report on Wednesday, February 12th. Cantor Fitzgerald restated a “neutral” rating and set a $80.00 price objective on shares of Gilead Sciences in a report on Wednesday, December 11th. UBS Group upped their price objective on shares of Gilead Sciences from $70.00 to $96.00 and gave the company a “neutral” rating in a report on Thursday, November 21st. Daiwa America upgraded shares of Gilead Sciences to a “hold” rating in a report on Monday, November 18th. Finally, Morgan Stanley upped their target price on Gilead Sciences from $123.00 to $130.00 and gave the company an “overweight” rating in a research report on Tuesday. Eleven investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have given a strong buy rating to the company. According to MarketBeat.com, Gilead Sciences currently has an average rating of “Moderate Buy” and a consensus price target of $104.52.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.